Company in the news: Carillion

Construction services firm Carillion’s (LSE: CLLN) proposed merger with Balfour Beatty (LSE: BBY) has hit the rocks. Carillion wanted the deal to include Balfour’s Parsons Brinckerhoff business, which would bring stable profits and strong cash flow. Balfour Beatty had already put this business up for sale and said “no”.

Carillion is a well-managed business and does a good job building things for the government and then looking after them. However, it has struggled to grow its profits organically over the last five years. The company has a record of growing by buying other companies.

During the last decade, it has hoovered up rivals, such as Mowlem and Alfred McAlpine, and benefited from big cost savings by combining them with its own businesses. Without these deals, Carillion’s profits would probably have been a lot lower. Balfour Beatty would have undoubtedly given it the option to do the same again.

Yet, growing by acquisition and mergers is a difficult way to make shareholders richer and many companies fail to do so. Carillion’s shares are not much higher than they were five years ago. Until it can prove that it is capable of sustainable profits growth from its existing businesses, the market is unlikely to place a higher value on the stock.

Verdict: avoid

• Stay up to date with MoneyWeek: Follow us on TwitterFacebook and Google+

MoneyWeek magazine

Latest issue:

Magazine cover
China's cash problem

How to profit from it

The UK's best-selling financial magazine. Take a FREE trial today.
Claim 4 FREE Issues

Bill Bonner: hold on to your cash, the real financial crisis is yet to come

Merryn Somerset Webb talks to Bill Bonner about economic cycles, and the 'catastrophic credit crisis' that will make 2008 look like a picnic.


Which investment platform?

When it comes to buying shares and funds, there are several investment platforms and brokers to choose from. They all offer various fee structures to suit individual investing habits.
Find out which one is best for you.


6 March 1899: Bayer trademarks Aspirin

Chemical company Bayer was awarded a patent for its pain-relieving acetylsalicylic acid powder, or 'Aspirin', on this day in 1899. It would soon be released in tablet form.